93271-75-1

Usage

Uses

Used in Pharmaceutical Synthesis:
DiMethyl 2-(2-PyriMidyl)Malonate is used as a building block for the synthesis of pharmaceuticals due to its unique structural features and reactivity. Its presence in the synthesis process allows for the creation of a diverse range of medicinal compounds with potential therapeutic applications.
Used in Agrochemical Synthesis:
In the agrochemical industry, DiMethyl 2-(2-PyriMidyl)Malonate serves as a key intermediate in the production of various agrochemicals. Its incorporation into these compounds can enhance their effectiveness in agricultural applications, such as pest control and crop protection.
Used in Cancer Research:
DiMethyl 2-(2-PyriMidyl)Malonate is used as a potential antitumor agent in cancer research. Its unique chemical structure allows it to interact with biological targets, potentially leading to the development of new cancer therapies. Researchers are exploring its ability to modulate cellular processes and inhibit the growth of cancer cells, offering hope for more effective treatments in the future.

InChI:InChI=1/C9H10N2O4/c1-14-8(12)6(9(13)15-2)7-10-4-3-5-11-7/h3-6H,1-2H3

Upstream product

• 4595-60-2 2-bromopyrimidine 
• 108-59-8 malonic acid dimethyl ester 
• 18424-76-5 dimethyl malonate sodium salt 
• 14161-09-2 2-methylsulphonyl-pyrimidine 

Downstream Products

• 5053-43-0 2-methylpyrimidine 

Relevant academic research and scientific papers

Discovery of functionally selective 7,8,9,10-tetrahydro-7,10-ethano-1,2,4- triazolo[3,4-a]phthalazines as GABAA receptor agonists at the α3 subunit

We have previously identified the 7,8,9,10-tetrahydro-7,10-ethano-1,2,4- triazolo[3,4-a]phthalazine (1) as a potent partial agonist for the 0.3 receptor subtype with 5-fold selectivity in binding affinity over α1. This paper describes a detailed investigation of the substituents on this core structure at both the 3- and 6-positions. Despite evaluating a wide range of groups, the maximum selectivity that could be achieved in terms of affinity for the α3 subtype over the α1 subtype was 12-fold (for 57). Although most analogues showed no selectivity in terms of efficacy, some did show partial agonism at α1 and antagonism at α3 (e.g., 25 and 75). However, two analogues tested (93 and 96), both with triazole substituents in the 6-position, showed significantly higher efficacy for the α3 subtype over the α1 subtype. This was the first indication that selectivity in efficacy in the required direction could be achieved in this series.

Substituted triazolo-pyridazine derivatives as ligands for GABA receptors

Substituted triazolo-pyridazine derivative compounds represented by wherein the variables are disclosed herein are selective ligands for GABA-A receptors, particularly for the α2 and/or α3 subunits.

TAUTOMERISM OF AZINE DERIVATIVES. 6.* TAUTOMERISM OF 2-PYRIMIDINYLMETHANE DERIVATIVES

The existence of a pyrimidinyl-pyrimidinylidene tautomeric equilibrium in solutions of 2-pyrimidinylcyanoacetic acid esters in CDCl3 was observed.Unsymmetrically substituted compounds form two types of ylidene tautomers that differ with respect to the position of the NH proton, the ratio between which is controlled by the substituents in the 4(6) position.The introduction of both donor and acceptor substituents into the 5 position of the pyrimidine ring increase the amount of the pyrimidine form.The same thing occurs when the polarity of the solvent is decreased.The addition of DMSO or DMF to CDCl3 leads to conversion of the intrachelate ylidene tautomers to unchelated tautomers.Protonation (CF3COOH) shifts the equilibrium to favor the ylidene tautomers has higher basicity.